Author

Lucas Blasco-Agell

Bellvitge University HospitalORCID 0000-0002-4640-4823Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Research Focus:cell-cell communication· 1 Approach:experimental assay· 1 Assay:imaging· 1

Frequent Co-Authors

Ángel RayaiD· 2 shared Antonella ConsiglioiD· 2 shared Irene Fernández‐CarasaiD· 2 shared Manel JuaniD· 2 shared Meritxell Pons‐EspinaliD· 2 shared Valentina BaruffiiD· 2 shared Yvonne Richaud‐PatíniD· 2 shared Alícia GarridoiD· 1 shared

Activity by Year

2024-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCell Biology

Ángel RayaORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

LRRK2-mutant microglia and neuromelanin synergize to drive dopaminergic neurodegeneration in an iPSC-based Parkinson's disease model

Lucas Blasco-Agell, Meritxell Pons‐Espinal, Veronica Testa, Gerard Roch, Jara Montero-Muñoz, Irene Fernández‐Carasa, Valentina Baruffi, Marta González-Sepúlveda, Yvonne Richaud‐Patín, Senda Jiménez‐Delgado, Thais Cuadros, Joana M. Cladera-Sastre, Joan Compte, Zoe Manglano-Artuñedo, Salvador Ventura, , Antonella Consiglio

LRRK2 G2019S iPSC-derived microglia exposed to neuromelanin, but not α-synuclein fibrils, reduce healthy dopaminergic neuron numbers in co-culture; ivermectin prevents this, and post-mortem midbrain supports it.

Communications Biology · Aug 12, 2025Peer-reviewedCell Biology✦ In-depth digest

Immunosuppressive tocilizumab prevents astrocyte induced neurotoxicity in hiPSC-LRRK2 Parkinson's disease by targeting receptor interleukin-6

Meritxell Pons‐Espinal, Lucas Blasco-Agell, Irene Fernández‐Carasa, Pol Andrés‐Benito, Angelique di Domenico, Yvonne Richaud‐Patín, Valentina Baruffi, Laura Marruecos, Lluı́s Espinosa, Alícia Garrido, EDUARDO S. TOLOSA, Michael J. Edel, Manel Juan, José Luis Mosquera, Isidró Ferrer, , Antonella Consiglio

The paper shows that tocilizumab, an IL-6 receptor inhibitor, prevents astrocyte-induced neurotoxicity in Parkinson's disease by blocking IL-6 signaling in neurons.

JCI Insight · Feb 8, 2024Peer-reviewedNeuroscience